cyclopentolate (Rx)

Brand and Other Names:Cyclogyl, AK-Pentolate
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

solution

  • 0.5%
  • 1%
  • 2%

Mydriasis/Cycloplegia Diaganosis

1-2 gtt of 1% solution in eye; may repeat in 5 minutes PRN; cycloplegia & mydriasis may last for 24 hours

Use 2% in heavily pigmented iris

Overdose Management

Ocular: Flush eyes w/water

Ingestion: Emesis, lavage

Severe systemic ADR's: Physostigmine

Dosage Forms & Strengths

solution

  • 0.5%
  • 1%
  • 2%

Mydriasis/Cycloplegia

1-2 gtt of 0.5%, 1% or 2% solution in eye; may repeat 5 minutes later by second application of 0.5% or 1% solution if necessary

Next:

Adverse Effects

Frequency Not Defined

Blurred vision

Burning sensation in eye

Light intolerance

Tachycardia

Conjunctivitis

Raised intraocular pressure

Hyperreactive response in Down's syndrome children (atropine)

Drowsiness

Previous
Next:

Warnings

Contraindications

Hypersensitivity to drug or components

Cautions

Remove contact lenses prior to administration and wait 15 min before reinserting

The elderly may be predisposed to increased intraocular pressure

Mydriatics may produce transient elevation of intraocular pressure; patients with untreated narrow-angle glaucoma or anatomically narrow angles may be susceptible to angle-closure following administration

Dropper tip is not to touch any surface, as this may contaminate the solution

A transient burning sensation may occur upon instillation

Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated

Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation

Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration

Feeding intolerance may follow ophthalmic use of this product in infants; it is recommended that feeding be withheld for 4 hours after examination

CNS effects

  • May cause central nervous system (CNS) disturbances, especially in younger age groups but may occur at any age, especially with stronger solutions
  • Infants are especially prone to CNS and cardiopulmonary side effects; to minimize absorption, use only 1 drop of 0.5% solution per eye, followed by pressure applied over nasolacrimal sac for two to three minutes; observe infants closely for at least 30 minutes following instillation

Previous
Next:

Pregnancy & Lactation

Pregnancy

Animal reproduction studies have not been conducted; not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity; administer to a pregnant woman only if clearly needed

Lactation

Not known whether this drug is excreted in human milk; because many drugs are excreted in human milk, exercise caution when drug is administered to a nursing woman

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Onset: rapid; max effect not for 30 min

Excretion: urine

Mechanism of Action

Blocks action of acetylcholine resulting in relaxation of the cholinergically innervated iris sphincter muscle

Cholinergic stimulation of accommodative ciliary muscle of lens is also blocked

Anticholinergic effects of cyclopentolate in eye produce dilation of the pupil (mydriasis) and paralysis of accommodation (cycloplegia)

Pharmacokinetics

Onset of action: 25-75 min (cycloplegia); 30-60 min (mydriasis)

Duration: < 24hr

Absorption: Minimal systemic

Previous
Next:

Images

BRAND FORM. UNIT PRICE PILL IMAGE
Cyclogyl ophthalmic (eye)
-
2 % drops
Cyclogyl ophthalmic (eye)
-
1 % drops
Cyclogyl ophthalmic (eye)
-
2 % drops
Cyclogyl ophthalmic (eye)
-
2 % drops
Cyclogyl ophthalmic (eye)
-
0.5 % drops
Cyclogyl ophthalmic (eye)
-
1 % drops
cyclopentolate ophthalmic (eye)
-
1 % drops
cyclopentolate ophthalmic (eye)
-
2 % drops
cyclopentolate ophthalmic (eye)
-
2 % drops
cyclopentolate ophthalmic (eye)
-
1 % drops
cyclopentolate ophthalmic (eye)
-
1 % drops
cyclopentolate ophthalmic (eye)
-
2 % drops
cyclopentolate ophthalmic (eye)
-
0.5 % drops
cyclopentolate ophthalmic (eye)
-
1 % drops
cyclopentolate ophthalmic (eye)
-
1 % drops
cyclopentolate ophthalmic (eye)
-
1 % drops

Copyright © 2010 First DataBank, Inc.

Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.